Key facts
- Neuspera’s last known valuation is $165.0M.
- It has raised $128.4M; the latest was Later Stage VC ($24.2M) in Jun 2024.
- Notable investors include Alumni Ventures, MedTech Innovator, Stanford University, Revelation Partners, PEAK6 Strategic Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Neuspera
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuspera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuspera
Developer of implantable medical devices designed to improve the lives of patients battling chronic illness. The company offers implantable neuromodulation devices that use mid-field powering techniques and can be implanted deep, enabling patients to get treatment options that are less invasive and more adaptable.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2013
- Employees
- 43
- Website
- neuspera.com/
- Ownership
- Privately Held (backing)
Neuspera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuspera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuspera in its N-PORT filings yet. We sweep new filings monthly.